期刊文献+

晚期非小细胞肺癌中β-tubulin Ⅲ表达水平对化学治疗敏感性的影响

Effect of beta-tubulin Ⅲ expression levels on chemotherapy sensitivity for advanced non-small cell lung cancer
下载PDF
导出
摘要 目的:分析非小细胞肺癌(non-small cell lung cancer,NSCLC)患者β-tubulin Ⅲ的表达水平与化学治疗(化疗)敏感性的关系。方法:经病理确诊的晚期NSCLC患者以1:2随机分配至对照组和基因型组:对照组使用吉西他滨联合顺铂化疗;基因型组根据ERCC1及RRM1的表达情况进行个体化治疗。检测病理标本中β-tubulin Ⅲ的表达水平,比较β-tubulin Ⅲ蛋白表达水平与临床疗效之间的关系。结果:基因型组最终有118例NSCLC病例可评价,均可成功检测β-tubulin Ⅲ的表达情况。对照组有效率(37.5%)与基因型组有效率(47.5%)比较,差异无统计学意义(P>0.05)。基因型组中各组间有效率比较,差异无统计学意义(P>0.05);但β-tubulinⅢ低表达组有效率(55.1%)显著高于β-tubulin Ⅲ高表达组(36.7%,P<0.05)。结论:在晚期NSCLC腺癌亚型中,β-tubulin Ⅲ低表达患者疗效较好,β-tubulin Ⅲ高表达可能意味着对多西他赛耐药。 Objective: To analyze the relation between β-tubulin Ⅲ expression level and chemosensitivity in non-small cell lung cancer (NSCLC). Methods: The patients were divided into a control group and a genotype group with a proportion of 1:2. The control group received the treatment of gemcitabin and cisplatin, while the genotype group received individual therapy according to the level of ERCC 1 and RRM1. The correlation between β-tubulin Ⅲexpression level and chemosensitivity in NSCLC was analyzed. Results β-Tubulin Ill expression was detected in all patients in the genotype group. Compared with the genotype group (47.5%), efficiency in the control group (37.5%) was not significantly different. Efficiency in patients with low expression of β-tubulin Ⅲ was significantly higher than that of patier.ts with high expression of β-tubulin Ⅲ (55.1% vs 36.7%, P〈0.05). Conclusion: In advanced NSCLC subtypes, patients with low expression of β-tubulin Ⅲ have good therapeutic effect. High β-tubulin Ⅲ expression may indicate resistance to docetaxel.
出处 《国际病理科学与临床杂志》 CAS 2013年第1期37-41,共5页 Journal of International Pathology and Clinical Medicine
基金 江苏省卫生厅面上项目(H200867)~~
关键词 非小细胞肺癌 Β-TUBULIN III ERCC1基因 RRM1基因 non-small cell lung cancer β-tubulin III ERCC1 gene RRM 1 gene
  • 相关文献

参考文献15

  • 1National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung CancerIEB/ OL].(2012-03-05) http: //www.nccn.org/pro fessionals/physician gls/ f guidelines.asp.
  • 2Fanucchi M, Khuri FR. Taxanes in the treatment of non-small cell lung cancer[J]. Treat Respir Med, 2006, S (3): 181-191.
  • 3Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC[J]. Lung Cancer, 2011, 71(1): 3410.
  • 4Bonomi M, Pilotto S, Milella M, et al. Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research [J].J Exp Clin Cancer Res, 201 1, 30( 12): 115.
  • 5许良中,杨文涛.免疫组织化学反应结果的判断标准[J].中国癌症杂志,1996,6(4):229-231. 被引量:1365
  • 6Xue C, Hu Z, Jiang W, et al. National survey of the medical treatment status for non-small cell lung cancer (NSCLC) in China[J]. LungCancer, 2012[Epub ahead of print].
  • 7Koh Y, Jang B, Han SWj et al. Expression of class III beta-tubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer[J].J Thorac Oncol, 2010, S(3): 320-32S.
  • 8Hayashi Y, Kuriyama H, Umezu H, et al. Class III beta-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small-cen lung cancer[J]. Intern Med, 2009, 48(4): 203-208.
  • 9Kang CH, Jang BG, Kim DW, et al. The prognostic significance of ERCC1, BRCAI, XRCC1, and betalII-tubulin expression in patients with non-small cell lung cancer treated by platinum- and taxane-based neoadjuvant chemotherapy and surgical resection[J]. Lung Cancer, 2010, 68(3): 478-483.
  • 10McCarroll JA, Gan PP, Liu M, et al. betalII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer[J]. Cancer Res, 2010, 70(12): 4995-5003.

二级参考文献3

共引文献1364

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部